Spyre Therapeutics, Inc. (SYRE)
(Delayed Data from NSDQ)
$16.36 USD
+0.12 (0.74%)
Updated Sep 29, 2025 03:59 PM ET
After-Market: $16.40 +0.04 (0.24%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SYRE 16.36 +0.12(0.74%)
Will SYRE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRE
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%
SYRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?
Other News for SYRE
Crossed Above 20 Day Moving Average appears for SYRE after 4.04% move
Fell Below 20 Day Moving Average appears for SYRE after 8.18% move
Deutsche Bank Initiates Coverage on Spyre Therapeutics (SYRE) with 'Buy' Rating | SYRE Stock News
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Spyre Therapeutics initiated with a Buy at Deutsche Bank